NASDAQ
15.06.26 | 20:11
3,850 US-Dollar
-0,90 % -0,035
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | C4 Therapeutics presents cemsidomide data at EHA congress | 1 | Investing.com | ||
| Do | C4 Therapeutics, Inc.: C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory ... | 1 | GlobeNewswire (USA) | ||
| Do | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 18.05. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.05. | C4 Therapeutics GAAP EPS of -$0.20 beats by $0.06, revenue of $6.15M beats by $1.73M | 1 | Seeking Alpha | ||
| 12.05. | C4 Therapeutics, Inc.: C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | 343 | GlobeNewswire (Europe) | Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab... ► Artikel lesen | |
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.05. | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.05. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | Roche places a $1bn bet on C4T degrader-antibody conjugates | 9 | pharmaphorum | ||
| 10.04. | Roche and C4 Therapeutics to advance degrader-antibody conjugates research | 7 | Pharmaceutical Technology | ||
| 10.04. | Roche kehrt mit Degrader-Deal zu C4 Therapeutics zurück | 29 | transkript.de | ||
| 09.04. | C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies | 14 | Benzinga.com | ||
| 09.04. | C4 Therapeutics inks new deal with Roche for degrader-antibody conjugates | 6 | Seeking Alpha | ||
| 09.04. | C4 Therapeutics Enters Collaboration Agreement With Roche | 517 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - C4 Therapeutics (CCCC) has entered into a new collaboration agreement with Roche (RHHBY, RO.SW, ROG.SW) to advance research in the degrader-antibody conjugate... ► Artikel lesen | |
| 09.04. | C4 Therapeutics, Roche partner on cancer degrader conjugates | 12 | Investing.com | ||
| 09.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 25.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma | 385 | GlobeNewswire (Europe) | WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 25.03. | Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock | 2 | Insider Monkey | ||
| 09.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 26.02. | Barclays raises C4 Therapeutics stock price target on trial progress | 9 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,064 | +1,33 % | Ocugen, Inc. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 0,997 | +4,35 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 26,340 | -2,52 % | Celldex Therapeutics, Inc.: Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting | ||
| CARDIFF ONCOLOGY | 1,310 | -2,53 % | Cardiff Oncology, Inc. - 8-K, Current Report | ||
| COHERUS ONCOLOGY | 1,200 | -0,50 % | Coherus Oncology, Inc.: Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $11.8 million in Q1 2026 - - Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 7,230 | +3,58 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| NEOVACS | 0,000 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.05.2026 | Das Instrument POH3 US14365C1036 CARNIVAL PLC ADR/1 DL1,66 EQUITY wird cum Kapitalmassnahme gehandelt am 06.05.2026 und ex Kapitalmassnahme am 07.05.2026 The instrument POH3 US14365C1036 CARNIVAL PLC... ► Artikel lesen | |
| ULTRAGENYX | 20,240 | 0,00 % | Ultragenyx Pharmaceutical Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| GYRE THERAPEUTICS | 5,200 | 0,00 % | GYRE THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| SAGIMET BIOSCIENCES | 5,320 | -0,37 % | Sagimet Biosciences Inc. - 8-K, Current Report | ||
| BIOMEA FUSION | 1,195 | +2,14 % | Biomea Fusion, Inc. - 8-K, Current Report | ||
| GOSSAMER BIO | 0,148 | +5,71 % | Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension | - Seralutinib demonstrated a placebo-adjusted improvement in Six-Minute Walk Distance (6MWD) of +13.3 meters at Week 24 (p = 0.0320), missing the prespecified alpha threshold of 0.025 -
- At week... ► Artikel lesen | |
| JANUX THERAPEUTICS | 13,760 | +1,51 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| 4D MOLECULAR THERAPEUTICS | 9,270 | +4,98 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| SOLID BIOSCIENCES | 7,170 | +0,42 % | Solid Biosciences Inc. - 8-K, Current Report |
Das Unternehmen C4 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,850 Euro und damit -0,90 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.